Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01855828 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01855828 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 50 participants.
The verdict
NCT01855828, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The main goal of this clinical trial is to test if adding pertuzumab (Perjeta), improves the anticancer activity of the combination chemotherapy regimen of trastuzumab (Herceptin) concomitant with paclitaxel, 5-fluorouracil, epirubicin, and cyclophosphamide (T-FEC). The study will also test the safety of this therapy.
Interventions
- DRUG Trastuzumab
- DRUG Paclitaxel
- DRUG 5-fluorouracil
- DRUG Pertuzumab
- DRUG Epirubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-09 |
| Est. Completion | 2018-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01855828
The ClinicalTrials.gov registry entry for NCT01855828 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Trastuzumab is the first listed.
NCT01855828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01855828 about?
NCT01855828 is a clinical study titled "Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer". The main goal of this clinical trial is to test if adding pertuzumab (Perjeta), improves the anticancer activity of the combination chemotherapy regimen of trastuzumab (Herceptin) concomitant with paclitaxel, 5-fluorouracil, epirubicin, and cyclophosphamide (T-FEC). The study will also test the safe...
What is the current status of trial NCT01855828?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2013-09. Estimated completion is 2018-08.
What interventions are being tested in trial NCT01855828?
The interventions under investigation include: Trastuzumab (DRUG), Paclitaxel (DRUG), 5-fluorouracil (DRUG), Pertuzumab (DRUG), Epirubicin (DRUG).
Who is sponsoring clinical trial NCT01855828?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.